Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions
Myelodysplastic SyndromesAcute Myeloid Leukemia
Interventions
DRUG

Imetelstat sodium

Intravenous injection

Trial Locations (11)

Unknown

Royal Adelaide Hospital, Adelaide

Royal Brisbane and Women's Hospitals, Brisbane

Linear Clinical Research, Nedlands

CHU Nantes - Hôtel Dieu, Nantes

Hôpital Archet 1, Nice

Hôpital Saint-Louis, Paris

CHU de Toulouse, Toulouse

Marien Hospital Düsseldorf, Düsseldorf

Universität Jena, Medizinische Fakultät, Jena

Universität Leipzig, Medizinische Fakultät, Leipzig

Klinikum rechts der Isar, München

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Geron Corporation

INDUSTRY

collaborator

Universitätsklinikum Leipzig

OTHER

collaborator

Saint-Louis Hospital, Paris, France

OTHER

collaborator

QIMR Berghofer Medical Research Institute

OTHER

collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

collaborator

Groupe Francophone des Myelodysplasies

OTHER

collaborator

German Myelodysplastic Syndrome Study Group

OTHER

lead

GCP-Service International West GmbH

INDUSTRY